GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Bloomage BioTechnology Corp Ltd (SHSE:688363) » Definitions » Debt-to-Equity

Bloomage BioTechnology (SHSE:688363) Debt-to-Equity : 0.06 (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Bloomage BioTechnology Debt-to-Equity?

Bloomage BioTechnology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥208 Mil. Bloomage BioTechnology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ¥203 Mil. Bloomage BioTechnology's Total Stockholders Equity for the quarter that ended in Mar. 2025 was ¥6,929 Mil. Bloomage BioTechnology's debt to equity for the quarter that ended in Mar. 2025 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bloomage BioTechnology's Debt-to-Equity or its related term are showing as below:

SHSE:688363' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01   Med: 0.04   Max: 0.18
Current: 0.06

During the past 9 years, the highest Debt-to-Equity Ratio of Bloomage BioTechnology was 0.18. The lowest was 0.01. And the median was 0.04.

SHSE:688363's Debt-to-Equity is ranked better than
84.52% of 1395 companies
in the Chemicals industry
Industry Median: 0.37 vs SHSE:688363: 0.06

Bloomage BioTechnology Debt-to-Equity Historical Data

The historical data trend for Bloomage BioTechnology's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bloomage BioTechnology Debt-to-Equity Chart

Bloomage BioTechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only 0.02 0.05 0.06 0.03 0.05

Bloomage BioTechnology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.03 0.04 0.05 0.06

Competitive Comparison of Bloomage BioTechnology's Debt-to-Equity

For the Specialty Chemicals subindustry, Bloomage BioTechnology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bloomage BioTechnology's Debt-to-Equity Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Bloomage BioTechnology's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bloomage BioTechnology's Debt-to-Equity falls into.


;
;

Bloomage BioTechnology Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bloomage BioTechnology's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Bloomage BioTechnology's Debt to Equity Ratio for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bloomage BioTechnology  (SHSE:688363) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Bloomage BioTechnology Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bloomage BioTechnology's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Bloomage BioTechnology Business Description

Traded in Other Exchanges
N/A
Address
No. 678 Tianchen Avenue, High-Tech Development Zone, Shandong Province, Jinan City, CHN
Bloomage BioTechnology Corp Ltd manufactures and sells a variety of chemicals and chemical-based products, typically made from hyaluronic acid sodium, or HA. The firm organizes itself into two segments based on product type. The HA raw materials segment, which generates the majority of revenue, sells HA and HA derivatives produced using bio-fermentation technology. The HA raw materials segment products are classified into three grades of HA: medicine grade, cosmetic grade, and food grade. The HA end products segment sells medical skin care products, bone products for intra-articular injection, and medical beauty devices. The majority of revenue comes from China.
Executives
Zhao Yi Core technical personnel
Luan Yi Hong Core technical personnel
Shi Yan Li Core technical personnel
Liu Jian Jian Core technical personnel
Wang Yu Ling Core technical personnel
Zhou Wei Core technical personnel
Huang Si Ling Core technical personnel
Han Hong Ling Core technical personnel
Lu Zhen Core technical personnel

Bloomage BioTechnology Headlines

No Headlines